SCHEMBL4186205

SCHEMBL4186205

CCCCCCCCOC1(C(=O)O)C=CC(c2ccccc2)C=C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.45
TSHR P16473 3/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP3A4 P08684 2/20 0.39
TP53 P04637 2/20 0.39
MAPK1 P28482 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
RECQL P46063 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CHRM2 P08172 2/20 0.38
NR1I2 O75469 1/20 0.38
ADRA2A P08913 1/20 0.38
MAPT P10636 1/20 0.38
OPRK1 P41145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9462288 1.00 PPARG (0.45) PPARGTSHRLMNAALDH1A1CYP3A4
SCHEMBL5828433 1.00 PPARG (0.45) PPARGTSHRLMNAALDH1A1CYP3A4
SCHEMBL4182081 1.00 PPARG (0.45) PPARGTSHRLMNAALDH1A1CYP3A4
SCHEMBL4184936 1.00 PPARG (0.45) PPARGTSHRLMNAALDH1A1CYP3A4
SCHEMBL11363522 1.00 PPARG (0.45) PPARGTSHRLMNAALDH1A1CYP3A4
SCHEMBL10580595 0.91 PPARG (0.44) PPARGTSHRLMNAALDH1A1CYP3A4
SCHEMBL9849450 0.91 PPARG (0.44) PPARGTSHRLMNAALDH1A1CYP3A4
SCHEMBL9852394 0.90 PPARG (0.43) PPARGTSHRLMNAALDH1A1CYP3A4
SCHEMBL10903892 0.89 PPARG (0.48) PPARGTSHRLMNAALDH1A1CYP3A4
SCHEMBL4083717 0.89 PPARG (0.43) PPARGTSHRLMNAALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS SONY CORPORATION (JP) 2009-07-09 US disclosed
EP-1907347-A2 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS Arcadia Pharmaceuticals Inc. (US) 2008-04-09 EP disclosed
WO-2007009083-A2 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2007-01-18 WO disclosed
EP-1456229-A2 METHOD FOR PREPARING ECHINOCANDIN DERIVATIVES Aventis Pharma S.A. (FR) 2004-09-15 EP disclosed
WO-2003054001-A2 METHOD FOR PREPARING ECHINOCANDIN DERIVATIVES AND THEIR COMPOSITIONS AVENTIS PHARMA S.A. (FR) 2003-07-03 WO disclosed
EP-0333760-B1 CYANO-ALICYCLIC ESTERS AND LIQUID CRYSTAL COMPOSITIONS THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN (GB) 1992-07-01 EP disclosed
EP-0422996-A2 Liquid crystal compound Showa Shell Sekiyu Kabushiki Kaisha (JP) 1991-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS RARB, RARA, RARG PPARG 46/4885TSHR 358/4885LMNA 4564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.